-
1
-
-
17944383059
-
Hepatitis C virus infection: The new global epidemic
-
Butt AA. Hepatitis C virus infection: The new global epidemic. Expert Rev Anti Infect Ther 2005;3:241-9.
-
(2005)
Expert Rev Anti Infect Ther
, vol.3
, pp. 241-249
-
-
Butt, A.A.1
-
3
-
-
34047262154
-
Viral hepatitis in HIV infection
-
Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-54.
-
(2007)
N Engl J Med
, vol.356
, pp. 1445-1454
-
-
Koziel, M.J.1
Peters, M.G.2
-
4
-
-
0025742696
-
Prevalence of antibody to hepatitis C virus among Saudi Arabian children: A community-based study
-
Al-Faleh FZ, Ayoola EA, al-Jeffry M, al-Rashed R, al-Mofarreh M, Arif M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: A community-based study. Hepatology 1991;14:215-8.
-
(1991)
Hepatology
, vol.14
, pp. 215-218
-
-
Al-Faleh, F.Z.1
Ayoola, E.A.2
Al-Jeffry, M.3
Al-Rashed, R.4
Al-Mofarreh, M.5
Arif, M.6
-
5
-
-
55949106358
-
Long-term protection of hepatitis B vaccine 18 years after vaccination
-
Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect 2008;57:404-9.
-
(2008)
J Infect
, vol.57
, pp. 404-409
-
-
Alfaleh, F.1
Alshehri, S.2
Alansari, S.3
Aljeffri, M.4
Almazrou, Y.5
Shaffi, A.6
-
6
-
-
0033395346
-
Hepatitis C: Prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia
-
Fakeeh M, Zaki AM. Hepatitis C: Prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. Am J Trop Med Hyg 1999;61:889-92.
-
(1999)
Am J Trop Med Hyg
, vol.61
, pp. 889-892
-
-
Fakeeh, M.1
Zaki, A.M.2
-
7
-
-
76449089170
-
Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia
-
Memish ZA, Knawy BA, El-Saed A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. Int J Infect Dis 2010;14:e115-20.
-
(2010)
Int J Infect Dis
, vol.14
-
-
Memish, Z.A.1
Knawy, B.A.2
El-Saed, A.3
-
8
-
-
0029103110
-
Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: A community-based study
-
Al-Faleh FZ, Ramia S, Arif M, Ayoola EA, al-Rashed RS, al-Jeffry M, et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: A community-based study. Ann Trop Med Parasitol 1995;89:431-7.
-
(1995)
Ann Trop Med Parasitol
, vol.89
, pp. 431-437
-
-
Al-Faleh, F.Z.1
Ramia, S.2
Arif, M.3
Ayoola, E.A.4
Al-Rashed, R.S.5
Al-Jeffry, M.6
-
9
-
-
0026774058
-
Intrafamilial transmission of hepatitis C virus (HCV): A major mode of spread in the Saudi Arabia population
-
Al Nasser MN. Intrafamilial transmission of hepatitis C virus (HCV): A major mode of spread in the Saudi Arabia population. Ann Trop Paediatr 1992;12:211-5.
-
(1992)
Ann Trop Paediatr
, vol.12
, pp. 211-215
-
-
Al Nasser, M.N.1
-
10
-
-
0025793770
-
Hepatitis C virus antibodies in high-risk Saudi groups
-
Bahakim H, Bakir TM, Arif M, Ramia S. Hepatitis C virus antibodies in high-risk Saudi groups. Vox Sang 1991;60:162-4.
-
(1991)
Vox Sang
, vol.60
, pp. 162-164
-
-
Bahakim, H.1
Bakir, T.M.2
Arif, M.3
Ramia, S.4
-
11
-
-
78149279576
-
Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors
-
Alswaidi FM, O'Brien SJ. Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors? J Epidemiol Community Health 2010;64:989-97.
-
(2010)
J Epidemiol Community Health
, vol.64
, pp. 989-997
-
-
Alswaidi, F.M.1
O'Brien, S.J.2
-
13
-
-
34447307115
-
Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance
-
Madani TA. Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance. Ann Saudi Med 2007;27:191-4.
-
(2007)
Ann Saudi Med
, vol.27
, pp. 191-194
-
-
Madani, T.A.1
-
14
-
-
0141521890
-
Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia
-
Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Med J 2003;24 Suppl 2:S87-91.
-
(2003)
Saudi Med J
, vol.24
, Issue.SUPPL. 2
-
-
Shobokshi, O.A.1
Serebour, F.E.2
Skakni, L.I.3
-
15
-
-
0027957612
-
Epidemiology of hepatitis C virus: A study of male blood donors in Saudi Arabia
-
Abdelaal M, Rowbottom D, Zawawi T, Scott T, Gilpin C. Epidemiology of hepatitis C virus: A study of male blood donors in Saudi Arabia. Transfusion 1994;34:135-7.
-
(1994)
Transfusion
, vol.34
, pp. 135-137
-
-
Abdelaal, M.1
Rowbottom, D.2
Zawawi, T.3
Scott, T.4
Gilpin, C.5
-
16
-
-
0348161558
-
Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades
-
Al-Faleh FZ. Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades. Ann Saudi Med 2003;23:367-71.
-
(2003)
Ann Saudi Med
, vol.23
, pp. 367-371
-
-
Al-Faleh, F.Z.1
-
17
-
-
34250753740
-
Hepatitis C in dialysis units: The Saudi experience
-
Karkar A. Hepatitis C in dialysis units: The Saudi experience. Hemodial Int 2007;11:354-67.
-
(2007)
Hemodial Int
, vol.11
, pp. 354-367
-
-
Karkar, A.1
-
18
-
-
85047695050
-
High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: A need for new dialysis strategies
-
Huraib S, al-Rashed R, Aldrees A, Aljefry M, Arif M, al-Faleh FA. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: A need for new dialysis strategies. Nephrol Dial Transplant 1995;10:470-4.
-
(1995)
Nephrol Dial Transplant
, vol.10
, pp. 470-474
-
-
Huraib, S.1
Al-Rashed, R.2
Aldrees, A.3
Aljefry, M.4
Arif, M.5
Al-Faleh, F.A.6
-
19
-
-
38149114109
-
Profile of viral hepatitis A, B, and C in a Saudi Arabian hospital
-
Al-Tawfiq JA, Anani A. Profile of viral hepatitis A, B, and C in a Saudi Arabian hospital. Med Sci Monit 2008;14:CR52-6.
-
(2008)
Med Sci Monit
, vol.14
-
-
Al-Tawfiq, J.A.1
Anani, A.2
-
20
-
-
1342310764
-
Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia
-
El-Hazmi MM. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia. Saudi Med J 2004;25:26-33.
-
(2004)
Saudi Med J
, vol.25
, pp. 26-33
-
-
El-Hazmi, M.M.1
-
21
-
-
79958698124
-
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
-
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31 Suppl 2:61-80.
-
(2011)
Liver Int
, vol.31
, Issue.SUPPL. 2
, pp. 61-80
-
-
Sievert, W.1
Altraif, I.2
Razavi, H.A.3
Abdo, A.4
Ahmed, E.A.5
Alomair, A.6
-
22
-
-
0029456220
-
Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia
-
Al-Faleh FZ, Huraib S, Sbeih F, al-Karawi M, al-Rashed R, al-Mofleh IA, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat 1995;2:293-6.
-
(1995)
J Viral Hepat
, vol.2
, pp. 293-296
-
-
Al-Faleh, F.Z.1
Huraib, S.2
Sbeih, F.3
Al-Karawi, M.4
Al-Rashed, R.5
Al-Mofleh, I.A.6
-
23
-
-
0030896591
-
Prevalence and clinical expression of HCV-genotypes in haemodialysis-patients of two geographically remote countries: Belgium and Saudi-Arabia
-
Bosmans JL, Nouwen EJ, Behets G, Gorteman K, Huraib SO, Shaheen FA, et al. Prevalence and clinical expression of HCV-genotypes in haemodialysis- patients of two geographically remote countries: Belgium and Saudi-Arabia. Clin Nephrol 1997;47:256-62.
-
(1997)
Clin Nephrol
, vol.47
, pp. 256-262
-
-
Bosmans, J.L.1
Nouwen, E.J.2
Behets, G.3
Gorteman, K.4
Huraib, S.O.5
Shaheen, F.A.6
-
24
-
-
0032959638
-
Hepatitis C genotypes and subtypes in Saudi Arabia
-
Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999;58:44-8.
-
(1999)
J Med Virol
, vol.58
, pp. 44-48
-
-
Shobokshi, O.A.1
Serebour, F.E.2
Skakni, L.3
Al-Saffy, Y.H.4
Ahdal, M.N.5
-
25
-
-
13844255345
-
Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients
-
Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004;25:1935-8.
-
(2004)
Saudi Med J
, vol.25
, pp. 1935-1938
-
-
Al-Traif, I.1
Handoo, F.A.2
Al-Jumah, A.3
Al-Nasser, M.4
-
26
-
-
8344273577
-
Management of hepatitis C virus genotype 4
-
Abdo A, Lee S.Management of hepatitis C virus genotype 4.J Gastroenterol Hepatol 2004;19:1233-9.
-
(2004)
J Gastroenterol Hepatol
, vol.19
, pp. 1233-1239
-
-
Abdo, A.1
Lee, S.2
-
28
-
-
77955476107
-
Prevention of hepatitis C virus in hemodialysis patients: Five years experience from a single center
-
Mohamed WZ. Prevention of hepatitis C virus in hemodialysis patients: Five years experience from a single center. Saudi J Kidney Dis Transpl 2010;21:548-54.
-
(2010)
Saudi J Kidney Dis Transpl
, vol.21
, pp. 548-554
-
-
Mohamed, W.Z.1
-
29
-
-
79952045587
-
Methods used to reduce the prevalence of hepatitis C in a dialysis unit
-
Hussein MM, Mooij JM. Methods used to reduce the prevalence of hepatitis C in a dialysis unit. Saudi J Kidney Dis Transpl 2010;21:909-13.
-
(2010)
Saudi J Kidney Dis Transpl
, vol.21
, pp. 909-913
-
-
Hussein, M.M.1
Mooij, J.M.2
-
30
-
-
0000818590
-
The effect of chemical and heat disinfection of the hemodialysis machines on the spread of hepatitis C virus infection: A prospective study
-
Abu-Aisha H, Mitwalli A, Huraib SO, Al-Wakeel J, Abid J, Yousif KI, et al. The effect of chemical and heat disinfection of the hemodialysis machines on the spread of hepatitis C virus infection: A prospective study. Saudi J Kidney Dis Transpl 1995;6:174-8.
-
(1995)
Saudi J Kidney Dis Transpl
, vol.6
, pp. 174-178
-
-
Abu-Aisha, H.1
Mitwalli, A.2
Huraib, S.O.3
Al-Wakeel, J.4
Abid, J.5
Yousif, K.I.6
-
31
-
-
0030089396
-
Hepatitis C antibodies in haemodialysis and pattern of end-stage renal failure in Gassim, Saudi Arabia
-
Soyannwo MA, Khan N, Kommajosyula S, Abdel Rahman AR, Khadaji M, Sing R, et al. Hepatitis C antibodies in haemodialysis and pattern of end-stage renal failure in Gassim, Saudi Arabia. Afr J Med Med Sci 1996;25:13-22.
-
(1996)
Afr J Med Med Sci
, vol.25
, pp. 13-22
-
-
Soyannwo, M.A.1
Khan, N.2
Kommajosyula, S.3
Abdel Rahman, A.R.4
Khadaji, M.5
Sing, R.6
-
32
-
-
0037323333
-
Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east
-
Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control 2003;31:26-33.
-
(2003)
Am J Infect Control
, vol.31
, pp. 26-33
-
-
Saxena, A.K.1
Panhotra, B.R.2
Sundaram, D.S.3
Naguib, M.4
Venkateshappa, C.K.5
Uzzaman, W.6
-
33
-
-
34250777583
-
Hepatitis C virus infection among patients on hemodialysis in jeddah: A single center experience
-
Al-Jiffri AM, Fadag RB, Ghabrah TM, Ibrahim A. Hepatitis C virus infection among patients on hemodialysis in jeddah: A single center experience. Saudi J Kidney Dis Transpl 2003;14:84-9.
-
(2003)
Saudi J Kidney Dis Transpl
, vol.14
, pp. 84-89
-
-
Al-Jiffri, A.M.1
Fadag, R.B.2
Ghabrah, T.M.3
Ibrahim, A.4
-
35
-
-
33845919194
-
Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia
-
Madani TA. Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia. Trans R Soc Trop Med Hyg 2007;101:278-83.
-
(2007)
Trans R Soc Trop Med Hyg
, vol.101
, pp. 278-283
-
-
Madani, T.A.1
-
36
-
-
0033967172
-
Substance dependence. A hospital based survey
-
Iqbal N. Substance dependence. A hospital based survey. Saudi Med J 2000;21:51-7.
-
(2000)
Saudi Med J
, vol.21
, pp. 51-57
-
-
Iqbal, N.1
-
37
-
-
0032538246
-
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centre for disease control and prevention
-
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centre for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39.
-
(1998)
MMWR Recomm Rep
, vol.47
, Issue.RR19
, pp. 1-39
-
-
-
38
-
-
0037087144
-
Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials group
-
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis 2002;34:831-7.
-
(2002)
Clin Infect Dis
, vol.34
, pp. 831-837
-
-
Sherman, K.E.1
Rouster, S.D.2
Chung, R.T.3
Rajicic, N.4
-
39
-
-
0030093433
-
Risk of hepatitis C virus infection among household contacts of Saudi patients with chronic liver disease
-
Arif M, al-Swayeh M, al-Faleh FZ, Ramia S. Risk of hepatitis C virus infection among household contacts of Saudi patients with chronic liver disease. J Viral Hepat 1996;3:97-101.
-
(1996)
J Viral Hepat
, vol.3
, pp. 97-101
-
-
Arif, M.1
Al-Swayeh, M.2
Al-Faleh, F.Z.3
Ramia, S.4
-
40
-
-
0029166609
-
Hepatitis C acquisition in Saudi Arabia: Are the majority of cases without risk factor
-
Altraif I. Hepatitis C acquisition in Saudi Arabia: Are the majority of cases without risk factor? Ann Saudi Med 1995;15:428-30.
-
(1995)
Ann Saudi Med
, vol.15
, pp. 428-430
-
-
Altraif, I.1
-
41
-
-
84867316175
-
Schistosomiasis as a possible risk factor for acquiring hepatitis C virus (HCV) infection among Saudis
-
Arif MA, Al-Faleh FZ, Ramia S. Schistosomiasis as a possible risk factor for acquiring hepatitis C virus (HCV) infection among Saudis. Saudi J Gastroenterol 1997;3:74-7.
-
(1997)
Saudi J Gastroenterol
, vol.3
, pp. 74-77
-
-
Arif, M.A.1
Al-Faleh, F.Z.2
Ramia, S.3
-
42
-
-
0008550346
-
Age-specific prevelance of antibody to hepatitis C virus (HCV) among the Saudi population
-
Bakir T. Age-specific prevelance of antibody to hepatitis C virus (HCV) among the Saudi population. Saudi Med J 1992;13:321-4.
-
(1992)
Saudi Med J
, vol.13
, pp. 321-324
-
-
Bakir, T.1
-
43
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
American Association for the Study of Liver Diseases
-
Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
45
-
-
0028293828
-
A proposed system for nomenclature of hepatitis C viral genotypes
-
Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-4.
-
(1994)
Hepatology
, vol.19
, pp. 1321-1324
-
-
Simmonds, P.1
Alberti, A.2
Alter, H.J.3
Bonino, F.4
Bradley, D.W.5
Brechot, C.6
-
46
-
-
1542350630
-
-
NIH Consensus Statement on Management of Hepatitis C: 2002
-
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements 2002; 19 (3): 1-46.
-
(2002)
NIH Consensus and State-of-the-Science Statements
, vol.19
, Issue.3
, pp. 1-46
-
-
-
47
-
-
0029894579
-
The natural history of chronic hepatitis C infection
-
Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324-8.
-
(1996)
Eur J Gastroenterol Hepatol
, vol.8
, pp. 324-328
-
-
Strader, D.B.1
Seeff, L.B.2
-
48
-
-
0036828840
-
National institutes of health consensus development conference: Management of hepatitis C: 2002
-
Seeff LB, Hoofnagle JH. National institutes of health consensus development conference: Management of hepatitis C: 2002. Hepatology 2002;36 (5 Suppl 1):S1-2.
-
(2002)
Hepatology
, vol.36
, Issue.5 SUPPL. 1
-
-
Seeff, L.B.1
Hoofnagle, J.H.2
-
49
-
-
0027050805
-
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group
-
Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
-
(1992)
N Engl J Med
, vol.327
, pp. 1906-1911
-
-
Seeff, L.B.1
Buskell-Bales, Z.2
Wright, E.C.3
Durako, S.J.4
Alter, H.J.5
Iber, F.L.6
-
50
-
-
33645071042
-
High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives
-
Scott JD, McMahon BJ, Bruden D,Sullivan D, Homan C, Christensen C, et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives.Clin Infect Dis2006;42:945-52.
-
(2006)
Clin Infect Dis
, vol.42
, pp. 945-952
-
-
Scott, J.D.1
McMahon, B.J.2
Bruden, D.3
Sullivan, D.4
Homan, C.5
Christensen, C.6
-
51
-
-
0030744373
-
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C
-
Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-5.
-
(1997)
European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol
, vol.27
, pp. 201-205
-
-
Fattovich, G.1
Giustina, G.2
Degos, F.3
Diodati, G.4
Tremolada, F.5
Nevens, F.6
-
52
-
-
0031473399
-
Chronic hepatitis C virus disease: An evaluation of procedures for diagnosis and treatment
-
Stadhouders PH, Cooreman MP. Chronic hepatitis C virus disease: An evaluation of procedures for diagnosis and treatment. Neth J Med 1997;51:213-24.
-
(1997)
Neth J Med
, vol.51
, pp. 213-224
-
-
Stadhouders, P.H.1
Cooreman, M.P.2
-
53
-
-
0034897115
-
Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C
-
Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001;46:1677-83.
-
(2001)
Dig Dis Sci
, vol.46
, pp. 1677-1683
-
-
Adinolfi, L.E.1
Utili, R.2
Andreana, A.3
Tripodi, M.F.4
Marracino, M.5
Gambardella, M.6
-
54
-
-
0032837102
-
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group
-
Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
-
(1999)
Hepatology
, vol.30
, pp. 1054-1058
-
-
Benhamou, Y.1
Bochet, M.2
Di Martino, V.3
Charlotte, F.4
Azria, F.5
Coutellier, A.6
-
55
-
-
0030933395
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
-
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
-
(1997)
Lancet
, vol.349
, pp. 825-832
-
-
Poynard, T.1
Bedossa, P.2
Opolon, P.3
-
56
-
-
0035895302
-
The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse
-
Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120-4.
-
(2001)
Ann Intern Med
, vol.134
, pp. 120-124
-
-
Harris, D.R.1
Gonin, R.2
Alter, H.J.3
Wright, E.C.4
Buskell, Z.J.5
Hollinger, F.B.6
-
57
-
-
0026320833
-
Long-term clinical and histopathological follow-up of chronic post transfusion hepatitis
-
Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post transfusion hepatitis. Hepatology 1991;14:969-74.
-
(1991)
Hepatology
, vol.14
, pp. 969-974
-
-
Di Bisceglie, A.M.1
Goodman, Z.D.2
Ishak, K.G.3
Hoofnagle, J.H.4
Melpolder, J.J.5
Alter, H.J.6
-
58
-
-
79960088920
-
Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C
-
Sanai FM, Helmy A, Dale C, Al-Ashgar H, Abdo AA, Katada K, et al. Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C. Liver Int 2011;31:1039-46.
-
(2011)
Liver Int
, vol.31
, pp. 1039-1046
-
-
Sanai, F.M.1
Helmy, A.2
Dale, C.3
Al-Ashgar, H.4
Abdo, A.A.5
Katada, K.6
-
59
-
-
15844431546
-
The long-term pathological evolution of chronic hepatitis C
-
Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
-
(1996)
Hepatology
, vol.23
, pp. 1334-1340
-
-
Yano, M.1
Kumada, H.2
Kage, M.3
Ikeda, K.4
Shimamatsu, K.5
Inoue, O.6
-
60
-
-
0034802790
-
Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C
-
Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32:904-9.
-
(2001)
Hum Pathol
, vol.32
, pp. 904-909
-
-
Fontaine, H.1
Nalpas, B.2
Poulet, B.3
Carnot, F.4
Zylberberg, H.5
Brechot, C.6
-
61
-
-
47649121791
-
-
Bethesda, MD: NIH Pub. No. 06-5873
-
Freedman L, Edwards B, Ries L, Young Je, editors. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. Bethesda, MD: NIH Pub No. 06-5873; 2006.
-
(2006)
Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER
-
-
Freedman, L.1
Edwards, B.2
Ries, L.3
Young, J.E.4
-
62
-
-
42249114810
-
-
database on the Internet.[Last cited on 2011 Apr24]
-
Magnitude of hepatocellular carcinoma in Egypt [database on the Internet]. Available from: http://www.nci.edu.eg.[Last cited on 2011 Apr24].
-
Magnitude of Hepatocellular Carcinoma in Egypt
-
-
-
63
-
-
0029000657
-
Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6
-
Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El-Zayadi AR, et al. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virol 1995;76 (Pt 7):1737-48.
-
(1995)
J Gen Virol
, vol.76
, Issue.PART 7
, pp. 1737-1748
-
-
Bhattacherjee, V.1
Prescott, L.E.2
Pike, I.3
Rodgers, B.4
Bell, H.5
El-Zayadi, A.R.6
-
64
-
-
0031047036
-
Chronic liver disease in the Alexandria governorate, Egypt: Contribution of schistosomiasis and hepatitis virus infections
-
Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: Contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997;26:236-43.
-
(1997)
J Hepatol
, vol.26
, pp. 236-243
-
-
Angelico, M.1
Renganathan, E.2
Gandin, C.3
Fathy, M.4
Profili, M.C.5
Refai, W.6
-
65
-
-
0033943125
-
Clinical, virological and histopathological features: Long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni
-
Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: Long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000;20:281-9.
-
(2000)
Liver
, vol.20
, pp. 281-289
-
-
Kamal, S.1
Madwar, M.2
Bianchi, L.3
Tawil, A.E.4
Fawzy, R.5
Peters, T.6
-
66
-
-
58149311491
-
Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta-analysis
-
Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta-analysis. Int J Cancer 2009;124:690-7.
-
(2009)
Int J Cancer
, vol.124
, pp. 690-697
-
-
Lehman, E.M.1
Wilson, M.L.2
-
67
-
-
0031041924
-
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
-
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
-
(1997)
Gastroenterology
, vol.112
, pp. 463-472
-
-
Fattovich, G.1
Giustina, G.2
Degos, F.3
Tremolada, F.4
Diodati, G.5
Almasio, P.6
-
68
-
-
0032955838
-
The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States
-
Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-6.
-
(1999)
Hepatology
, vol.29
, pp. 1311-1316
-
-
Hu, K.-Q.1
Tong, M.J.2
-
69
-
-
11144356775
-
Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients
-
Planas, R, Ballesté, B, Alvarez, MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-30.
-
(2004)
J Hepatol
, vol.40
, pp. 823-830
-
-
Planas, R.1
Ballesté, B.2
Alvarez, M.A.3
Rivera, M.4
Montoliu, S.5
Galeras, J.A.6
-
70
-
-
12944264864
-
Current patterns of hepatitis C virus transmission in United States: The role of drugs and sex (Abstract)
-
Williams IT, Sabin K, Fleenor M, Judson F, Mottram K, Poujade J, et al. Current patterns of hepatitis C virus transmission in United States: The role of drugs and sex (Abstract). Hepatology 1998;28:497A.
-
(1998)
Hepatology
, vol.28
-
-
Williams, I.T.1
Sabin, K.2
Fleenor, M.3
Judson, F.4
Mottram, K.5
Poujade, J.6
-
72
-
-
0027017129
-
Hepatitis C: Molecular biology, pathogenesis, epidemiology, clinical features, and prevention
-
Esteban JI, Genesca J, Alter HJ. Hepatitis C: Molecular biology, pathogenesis, epidemiology, clinical features, and prevention. Prog Liver Dis 1992;10:253-82.
-
(1992)
Prog Liver Dis
, vol.10
, pp. 253-282
-
-
Esteban, J.I.1
Genesca, J.2
Alter, H.J.3
-
73
-
-
0032835069
-
Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus
-
Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus. Gut 1999;45:613-7.
-
(1999)
Gut
, vol.45
, pp. 613-617
-
-
Chu, C.M.1
Yeh, C.T.2
Liaw, Y.F.3
-
74
-
-
0033023854
-
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
-
Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
-
(1999)
Hepatology
, vol.29
, pp. 908-914
-
-
Villano, S.A.1
Vlahov, D.2
Nelson, K.E.3
Cohn, S.4
Thomas, D.L.5
-
75
-
-
33645067930
-
Extrahepatic manifestations of hepatitis C virus
-
Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 2006;8:53-9.
-
(2006)
Curr Gastroenterol Rep
, vol.8
, pp. 53-59
-
-
Sterling, R.K.1
Bralow, S.2
-
76
-
-
0029068653
-
Hepatitis C associated glomerulonephritis
-
Altraif IH, Abdulla AS, al Sebayel MI, Said RA, al Suhaibani MO, Jones AA. Hepatitis C associated glomerulonephritis.Am J Nephrol 1995;15:407-10.
-
(1995)
Am J Nephrol
, vol.15
, pp. 407-410
-
-
Altraif, I.H.1
Abdulla, A.S.2
Al Sebayel, M.I.3
Said, R.A.4
Al Suhaibani, M.O.5
Jones, A.A.6
-
77
-
-
5444245634
-
Hepatitis C virus-associated extrahepatic manifestations: A review
-
Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: A review. Metab Brain Dis 2004;19:357-81.
-
(2004)
Metab Brain Dis
, vol.19
, pp. 357-381
-
-
Sène, D.1
Limal, N.2
Cacoub, P.3
-
78
-
-
0030133050
-
Extrahepatic manifestations of hepatitis C
-
Gordon SC. Extrahepatic manifestations of hepatitis C. Dig Dis1996;14:157-68.
-
(1996)
Dig Dis
, vol.14
, pp. 157-168
-
-
Gordon, S.C.1
-
79
-
-
0037345674
-
Extrahepatic manifestations of hepatitis C infection
-
Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003;325:135-48.
-
(2003)
Am J Med Sci
, vol.325
, pp. 135-148
-
-
Mayo, M.J.1
-
80
-
-
0031952915
-
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
-
Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
-
(1998)
Hepatology
, vol.27
, pp. 868-872
-
-
Mathurin, P.1
Moussalli, J.2
Cadranel, J.F.3
Thibault, V.4
Charlotte, F.5
Dumouchel, P.6
-
82
-
-
0030931156
-
Hepatitis C and hepatocellular carcinoma
-
Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26(3 Suppl1):34S-8S.
-
(1997)
Hepatology
, vol.26
, Issue.3 SUPPL. 1
-
-
Di Bisceglie, A.M.1
-
84
-
-
33646121757
-
Chronic hepatitis C in patients with persistently normal alanine transaminase levels
-
Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. "Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006;4:645-52.
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 645-652
-
-
Shiffman, M.L.1
Diago, M.2
Tran, A.3
Pockros, P.4
Reindollar, R.5
Prati, D.6
-
85
-
-
0028937538
-
Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities
-
Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285-90.
-
(1995)
Hepatology
, vol.21
, pp. 285-290
-
-
Silini, E.1
Bono, F.2
Cividini, A.3
Cerino, A.4
Bruno, S.5
Rossi, S.6
-
86
-
-
0026800867
-
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
-
Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-8.
-
(1992)
Lancet
, vol.340
, pp. 697-698
-
-
Alberti, A.1
Morsica, G.2
Chemello, L.3
Cavalletto, D.4
Noventa, F.5
Pontisso, P.6
-
87
-
-
0029160459
-
Relationship of aminotransferases to liver histologicalstatus in chronic hepatitis C
-
Haber M, West A, Haber A, Reuben A. Relationship of aminotransferases to liver histologicalstatus in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-7.
-
(1995)
Am J Gastroenterol
, vol.90
, pp. 1250-1257
-
-
Haber, M.1
West, A.2
Haber, A.3
Reuben, A.4
-
88
-
-
0035076670
-
Sensitivity and specificity of third-generation hepatitis C virus antibodydetection assays: An analysis of the literature
-
Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibodydetection assays: An analysis of the literature. J Viral Hepat 2001;8:87-95.
-
(2001)
J Viral Hepat
, vol.8
, pp. 87-95
-
-
Colin, C.1
Lanoir, D.2
Touzet, S.3
Meyaud-Kraemer, L.4
Bailly, F.5
Trepo, C.6
-
89
-
-
0037372651
-
Low-positive anti-hepatitis C virus enzyme immunoassay results: An important predictor of low likelihood of hepatitis C infection
-
Dufour DR, Talastas M, Fernandez MD, Harris B, Strader DB, Seeff LB. Low-positive anti-hepatitis C virus enzyme immunoassay results: An important predictor of low likelihood of hepatitis C infection. Clin Chem 2003;49:479-86.
-
(2003)
Clin Chem
, vol.49
, pp. 479-486
-
-
Dufour, D.R.1
Talastas, M.2
Fernandez, M.D.3
Harris, B.4
Strader, D.B.5
Seeff, L.B.6
-
90
-
-
0037423405
-
Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centre for Disease Control and Prevention
-
Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centre for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1-13.
-
(2003)
MMWR Recomm Rep
, vol.52
, pp. 1-13
-
-
Alter, M.J.1
Kuhnert, W.L.2
Finelli, L.3
-
91
-
-
0031749658
-
What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories
-
Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998;27:1700-2.
-
(1998)
Hepatology
, vol.27
, pp. 1700-1702
-
-
Pawlotsky, J.M.1
Lonjon, I.2
Hezode, C.3
Raynard, B.4
Darthuy, F.5
Remire, J.6
-
92
-
-
0033789103
-
NAT of the United States and Canadian blood supply
-
Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000;40:1165-8.
-
(2000)
Transfusion
, vol.40
, pp. 1165-1168
-
-
Stramer, S.L.1
Caglioti, S.2
Strong, D.M.3
-
93
-
-
33745016896
-
Distribution of hepatitis C virus genotypes in the Middle East
-
Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis 2006;10:272-7.
-
(2006)
Int J Infect Dis
, vol.10
, pp. 272-277
-
-
Ramia, S.1
Eid-Fares, J.2
-
95
-
-
0028998229
-
Sensitivity and specificity of three third-generation antihepatitis C virus ELISAs
-
Vrielink H, Zaaijer HL, Reesink HW, van der Poe1 CL, Cuypers HT, Lelie PN. Sensitivity and specificity of three third-generation antihepatitis C virus ELISAs. VOX Sang 1995;69:14-7.
-
(1995)
VOX Sang
, vol.69
, pp. 14-17
-
-
Vrielink, H.1
Zaaijer, H.L.2
Reesink, H.W.3
Van Der Poel, C.L.4
Cuypers, H.T.5
Lelie, P.N.6
-
96
-
-
0028128878
-
Serologic diagnosis of viral hepatitis
-
Sjogren MH. Serologic diagnosis of viral hepatitis. Gastroenterol Clin North Am 1994;23:457-77.
-
(1994)
Gastroenterol Clin North Am
, vol.23
, pp. 457-477
-
-
Sjogren, M.H.1
-
97
-
-
0025993888
-
Recombinant immunoblot assay first and second generations on 732 blood donors reactive for antibodies to hepatitis C virus by ELISA
-
Courouce AM, Janot C. Recombinant immunoblot assay first and second generations on 732 blood donors reactive for antibodies to hepatitis C virus by ELISA. VOX Sang 1991;61:177-80.
-
(1991)
VOX Sang
, vol.61
, pp. 177-180
-
-
Courouce, A.M.1
Janot, C.2
-
98
-
-
0033966433
-
Screening for hepatitis C virus in human immunodeficiency virusinfected individuals
-
Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virusinfected individuals. J Clin Microbiol 2000;38:575-7.
-
(2000)
J Clin Microbiol
, vol.38
, pp. 575-577
-
-
Thio, C.L.1
Nolt, K.R.2
Astemborski, J.3
Vlahov, D.4
Nelson, K.E.5
Thomas, D.L.6
-
99
-
-
22844448860
-
Diagnostic discordance for hepatitis C virus infection in hemodialysis patients
-
Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005;46:290-300.
-
(2005)
Am J Kidney Dis
, vol.46
, pp. 290-300
-
-
Kalantar-Zadeh, K.1
Miller, L.G.2
Daar, E.S.3
-
100
-
-
0025607820
-
Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
-
Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. Aids 1990;4:1275-7.
-
(1990)
Aids
, vol.4
, pp. 1275-1277
-
-
Chamot, E.1
Hirschel, B.2
Wintsch, J.3
Robert, C.F.4
Gabriel, V.5
Deglon, J.J.6
-
101
-
-
57349116917
-
Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplificationassay (Versant HCV RNA 3. 0) for RNA detection and quantification
-
Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplificationassay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008;46:3880-91.
-
(2008)
J Clin Microbiol
, vol.46
, pp. 3880-3891
-
-
Vermehren, J.1
Kau, A.2
Gartner, B.C.3
Gobel, R.4
Zeuzem, S.5
Sarrazin, C.6
-
102
-
-
66749184153
-
Performance of the Abbott Real-Time PCR assay using m2000(sp) and m2000(rt) for hepatitis C virus RNA quantification
-
Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott Real-Time PCR assay using m2000(sp) and m2000(rt) for hepatitis C virus RNA quantification. J Clin Microbiol 2009;47:1726-32.
-
(2009)
J Clin Microbiol
, vol.47
, pp. 1726-1732
-
-
Chevaliez, S.1
Bouvier-Alias, M.2
Pawlotsky, J.M.3
-
103
-
-
34447503644
-
Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay
-
Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns MP, et al. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol 2007;39:308-11.
-
(2007)
J Clin Virol
, vol.39
, pp. 308-311
-
-
Fytili, P.1
Tiemann, C.2
Wang, C.3
Schulz, S.4
Schaffer, S.5
Manns, M.P.6
-
104
-
-
0036094158
-
Molecular diagnosis of viral hepatitis
-
Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-68.
-
(2002)
Gastroenterology
, vol.122
, pp. 1554-1568
-
-
Pawlotsky, J.M.1
-
105
-
-
0032954992
-
Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHOCollaborative Study Group
-
Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA.WHOCollaborative Study Group. Vox Sang 1999;76:149-58.
-
(1999)
Vox Sang
, vol.76
, pp. 149-158
-
-
Saldanha, J.1
Lelie, N.2
Heath, A.3
-
106
-
-
0033839969
-
Standardization of hepatitis C virus RNA quantification
-
Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32:654-9.
-
(2000)
Hepatology
, vol.32
, pp. 654-659
-
-
Pawlotsky, J.M.1
Bouvier-Alias, M.2
Hezode, C.3
Darthuy, F.4
Remire, J.5
Dhumeaux, D.6
-
107
-
-
0033787708
-
Efficacy of HCV core antigen detection during the preseroconversion period
-
Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000;40:1198-202.
-
(2000)
Transfusion
, vol.40
, pp. 1198-1202
-
-
Courouce, A.M.1
Le Marrec, N.2
Bouchardeau, F.3
Razer, A.4
Maniez, M.5
Laperche, S.6
-
108
-
-
84867296809
-
Detection of hepatitis C virus core antigen in blood donors using a new enzyme immunoassay
-
Alzahrani AJ, Obeid OE. Detection of hepatitis C virus core antigen in blood donors using a new enzyme immunoassay. J Fam Community Med 2004;11:103-7.
-
(2004)
J Fam Community Med
, vol.11
, pp. 103-107
-
-
Alzahrani, A.J.1
Obeid, O.E.2
-
109
-
-
29144503716
-
Analysis of HCV core antigenemia in Saudi Drug users
-
Alzahrani AJ. Analysis of HCV core antigenemia in Saudi Drug users. Saudi Med J 2005;26:1645-6.
-
(2005)
Saudi Med J
, vol.26
, pp. 1645-1646
-
-
Alzahrani, A.J.1
-
110
-
-
11844294967
-
Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients
-
Fabrizi F, Lunghi G, Aucella F, Mangano S, Barbisoni F, Bisegna S, et al. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol 2005;43:414-20.
-
(2005)
J Clin Microbiol
, vol.43
, pp. 414-420
-
-
Fabrizi, F.1
Lunghi, G.2
Aucella, F.3
Mangano, S.4
Barbisoni, F.5
Bisegna, S.6
-
111
-
-
11844265960
-
Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy
-
Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005;43:186-91.
-
(2005)
J Clin Microbiol
, vol.43
, pp. 186-191
-
-
Takahashi, M.1
Saito, H.2
Higashimoto, M.3
Atsukawa, K.4
Ishii, H.5
-
112
-
-
34047261253
-
Clinical assessment of Monolisa HCV Ag-Ab ULTRA (Bio-Rad) in a general hospital
-
Alados-Arboledas JC, Calbo-Torrecillas L, Lopez-Prieto MD, de Francisco-Ramirez JL, de Miguel-Sastre C. Clinical assessment of Monolisa HCV Ag-Ab ULTRA (Bio-Rad) in a general hospital. Enferm Infecc Microbiol Clin 2007;25:172-6.
-
(2007)
Enferm Infecc Microbiol Clin
, vol.25
, pp. 172-176
-
-
Alados-Arboledas, J.C.1
Calbo-Torrecillas, L.2
Lopez-Prieto, M.D.3
De Francisco-Ramirez, J.L.4
De Miguel-Sastre, C.5
-
113
-
-
65449136656
-
AASLD practice guidelines, diagnosis, management and treatment of hepatitis C: An update
-
Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines, diagnosis, management and treatment of hepatitis C: An update. Hepatology 2009;49:1335-74.
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
114
-
-
23744473330
-
Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection
-
Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant-Delmas A, Maniez-Montreuil M, et al. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005;43:3877-83.
-
(2005)
J Clin Microbiol
, vol.43
, pp. 3877-3883
-
-
Laperche, S.1
Le Marrec, N.2
Girault, A.3
Bouchardeau, F.4
Servant-Delmas, A.5
Maniez-Montreuil, M.6
-
115
-
-
33644874357
-
Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection
-
Ansaldi F, Bruzzone B, Testino G, Bassetti M, Gasparini R, Crovari P, et al. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. J Viral Hepat 2006;3:5-10.
-
(2006)
J Viral Hepat
, vol.3
, pp. 5-10
-
-
Ansaldi, F.1
Bruzzone, B.2
Testino, G.3
Bassetti, M.4
Gasparini, R.5
Crovari, P.6
-
116
-
-
0029135060
-
Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications
-
Gretch DR, Corazon dela Rosa MT, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications. Ann Intern Med 1995;123:321-9.
-
(1995)
Ann Intern Med
, vol.123
, pp. 321-329
-
-
Gretch, D.R.1
Corazon Dela Rosa, M.T.2
Carithers, R.L.3
Willson, R.A.4
Williams, B.5
Corey, L.6
-
117
-
-
59249106268
-
Diagnosis and management of chronic viralhepatitis: Antigens, antibodies and viral genomes
-
Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viralhepatitis: Antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 2008;22:1031-48.
-
(2008)
Best Pract Res Clin Gastroenterol
, vol.22
, pp. 1031-1048
-
-
Chevaliez, S.1
Pawlotsky, J.M.2
-
118
-
-
0027193025
-
Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3
-
Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3. J Clin Microbiol 1993;31:1493-503.
-
(1993)
J Clin Microbiol
, vol.31
, pp. 1493-1503
-
-
Simmonds, P.1
Rose, K.A.2
Graham, S.3
Chan, S.W.4
McOmish, F.5
Dow, B.C.6
-
119
-
-
0027214322
-
At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide
-
Bukh J, Purcell R, Miller R. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci USA 1993;90:8234-8.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 8234-8238
-
-
Bukh, J.1
Purcell, R.2
Miller, R.3
-
120
-
-
0028218513
-
Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions
-
Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 1994;75:1053-61.
-
(1994)
J Gen Virol
, vol.75
, pp. 1053-1061
-
-
Simmonds, P.1
Smith, D.B.2
McOmish, F.3
Yap, P.L.4
Kolberg, J.5
Urdea, M.S.6
-
121
-
-
0026563204
-
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
-
Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane, Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
-
(1992)
J Gen Virol
, vol.73
, pp. 673-679
-
-
Okamoto, H.1
Sugiyama, Y.2
Okada, S.3
Kurai, K.4
Akahane, Y.5
Sugai, Y.6
-
122
-
-
0027509074
-
Detection of three types of hepatitis C virus in blood donors: Investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities
-
McOmish F, Chan SW, Dow BC, Gillon J, Frame WD, Crawford RJ, et al. Detection of three types of hepatitis C virus in blood donors: Investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993;33:7-13.
-
(1993)
Transfusion
, vol.33
, pp. 7-13
-
-
McOmish, F.1
Chan, S.W.2
Dow, B.C.3
Gillon, J.4
Frame, W.D.5
Crawford, R.J.6
-
123
-
-
0027178527
-
Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
-
Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
-
(1993)
J Gen Virol
, vol.74
, pp. 1093-1102
-
-
Stuyver, L.1
Rossau, R.2
Wyseur, A.3
Duhamel, M.4
Vanderborght, B.5
Van Heuverswyn, H.6
-
124
-
-
0032796827
-
Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test
-
Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999;37:2625-30.
-
(1999)
J Clin Microbiol
, vol.37
, pp. 2625-2630
-
-
Germer, J.J.1
Rys, P.N.2
Thorvilson, J.N.3
Persing, D.H.4
-
125
-
-
3142742615
-
Evaluation of liver fibrosis: A concise review
-
Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004;99:1160-74.
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 1160-1174
-
-
Afdhal, N.H.1
Nunes, D.2
-
126
-
-
12344267742
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
-
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8-10.
-
(2004)
Comp Hepatol
, vol.3
, pp. 8-10
-
-
Poynard, T.1
Imbert-Bismut, F.2
Munteanu, M.3
Messous, D.4
Myers, R.P.5
Thabut, D.6
-
127
-
-
3242798959
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
-
Poynard T, Munteanu M, Imbert-Bismut F. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-55.
-
(2004)
Clin Chem
, vol.50
, pp. 1344-1355
-
-
Poynard, T.1
Munteanu, M.2
Imbert-Bismut, F.3
-
128
-
-
0042265556
-
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
-
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
-
(2003)
Hepatology
, vol.38
, pp. 518-526
-
-
Wai, C.T.1
Greenson, J.K.2
Fontana, R.J.3
Kalbfleisch, J.D.4
Marrero, J.A.5
Conjeevaram, H.S.6
-
129
-
-
0036789328
-
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
-
Forns X, Ampurdanes S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
-
(2002)
Hepatology
, vol.36
, pp. 986-992
-
-
Forns, X.1
Ampurdanes, S.2
Llovet, J.M.3
Aponte, J.4
Quintó, L.5
Martínez-Bauer, E.6
-
130
-
-
34547483053
-
FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest
-
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin- Venier V, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 2007;46:32-6.
-
(2007)
Hepatology
, vol.46
, pp. 32-36
-
-
Vallet-Pichard, A.1
Mallet, V.2
Nalpas, B.3
Verkarre, V.4
Nalpas, A.5
Dhalluin- Venier, V.6
-
131
-
-
33745547388
-
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
-
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
-
(2006)
Hepatology
, vol.43
, pp. 1317-1325
-
-
Sterling, R.K.1
Lissen, E.2
Clumeck, N.3
Sola, R.4
Correa, M.C.5
Montaner, J.6
-
132
-
-
33847705375
-
Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C
-
Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y, et al. Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306.
-
(2007)
Hepatology
, vol.45
, pp. 297-306
-
-
Koda, M.1
Matunaga, Y.2
Kawakami, M.3
Kishimoto, Y.4
Suou, T.5
Murawaki, Y.6
-
133
-
-
0035820265
-
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study
-
MULTIVIRC Group
-
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75.
-
(2001)
Lancet
, vol.357
, pp. 1069-1075
-
-
Imbert-Bismut, F.1
Ratziu, V.2
Pieroni, L.3
Charlotte, F.4
Benhamou, Y.5
Poynard, T.6
-
134
-
-
32144449983
-
A novel panel of blood markers to assess the degree of liver fibrosis
-
Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-8.
-
(2005)
Hepatology
, vol.42
, pp. 1373-1378
-
-
Calès, P.1
Oberti, F.2
Michalak, S.3
Hubert-Fouchard, I.4
Rousselet, M.C.5
Konaté, A.6
-
135
-
-
25444434632
-
Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection
-
Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
-
(2005)
Clin Chem
, vol.51
, pp. 1867-1873
-
-
Adams, L.A.1
Bulsara, M.2
Rossi, E.3
Deboer, B.4
Speers, D.5
George, J.6
-
136
-
-
62549128711
-
Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C
-
Borsoi Viana MS,Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol 2009;8:26-31.
-
(2009)
Ann Hepatol
, vol.8
, pp. 26-31
-
-
Borsoi Viana, M.S.1
Takei, K.2
Collarile Yamaguti, D.C.3
Guz, B.4
Strauss, E.5
-
137
-
-
79951689966
-
Fib4 is an independent predictor of serious liver disease among HIV-infected patients with or without HBV/HCV co-infection in the Icona foundation study. Italian Conference on AIDS and Retroviruses Brescia, Italy
-
Cozzi Lepri A, Prosperi M, Lo Caputo S, et al. Fib4 is an independent predictor of serious liver disease among HIV-infected patients with or without HBV/HCV co-infection in the Icona foundation study. Italian Conference on AIDS and Retroviruses Brescia, Italy. Infection 2010;38(Suppl 1):73.
-
(2010)
Infection
, vol.38
, Issue.SUPPL. 1
, pp. 73
-
-
Cozzi Lepri, A.1
Prosperi, M.2
Lo Caputo, S.3
-
138
-
-
60949101735
-
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus
-
Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, et al. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009;7:339-45.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 339-345
-
-
Tural, C.1
Tor, J.2
Sanvisens, A.3
Pérez-Alvarez, N.4
Martínez, E.5
Ojanguren, I.6
-
139
-
-
79953865880
-
Evaluation of liver fibrosis: Concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIVinfected patients without hepatitis C and B infection
-
Mendeni M, Focà E, Gotti D, Ladisa N, Angarano G, Albini L, et al. Evaluation of liver fibrosis: Concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIVinfected patients without hepatitis C and B infection. Clin Infect Dis 2011;52:1164-73.
-
(2011)
Clin Infect Dis
, vol.52
, pp. 1164-1173
-
-
Mendeni, M.1
Focà, E.2
Gotti, D.3
Ladisa, N.4
Angarano, G.5
Albini, L.6
-
140
-
-
79961112295
-
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C
-
Güzelbulut F, Cetinkaya ZA, Sezikli M, Yaşar B, Ozkara S, Övünç AO. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol 2011;22:279-85.
-
(2011)
Turk J Gastroenterol
, vol.22
, pp. 279-285
-
-
Güzelbulut, F.1
Cetinkaya, Z.A.2
Sezikli, M.3
Yaşar, B.4
Ozkara, S.5
Övünç, A.O.6
-
141
-
-
54349089348
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis
-
Halfon P, Munteanu M, Poynard T. "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". Gastroentérol Clin Biol 2008;32(6 Suppl 1): 22-39.
-
(2008)
Gastroentérol Clin Biol
, vol.32
, Issue.6 SUPPL. 1
, pp. 22-39
-
-
Halfon, P.1
Munteanu, M.2
Poynard, T.3
-
142
-
-
77955327158
-
Biomarkers of liver injury for hepatitis clinical trials: A meta-analysis of longitudinal studies
-
Poynard T, Ngo Y, Munteanu M, Thabut D, Massard J, Moussalli J, et al. Biomarkers of liver injury for hepatitis clinical trials: A meta-analysis of longitudinal studies. Antivir Ther 2010;15:617-31.
-
(2010)
Antivir Ther
, vol.15
, pp. 617-631
-
-
Poynard, T.1
Ngo, Y.2
Munteanu, M.3
Thabut, D.4
Massard, J.5
Moussalli, J.6
-
143
-
-
63549099586
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis
-
Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-14.
-
(2009)
J Viral Hepat
, vol.16
, pp. 300-314
-
-
Castera, L.1
-
144
-
-
0028952532
-
Histopathology of hepatitis C virus infection
-
Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
-
(1995)
Semin Liver Dis
, vol.15
, pp. 70-81
-
-
Goodman, Z.D.1
Ishak, K.G.2
-
145
-
-
0019813866
-
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
-
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
-
(1981)
Hepatology
, vol.1
, pp. 431-435
-
-
Knodell, R.G.1
Ishak, K.G.2
Black, W.C.3
Chen, T.S.4
Craig, R.5
Kaplowitz, N.6
-
146
-
-
0026072529
-
Classification of chronic viral hepatitis: A need for reassessment
-
Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991;13:372-4.
-
(1991)
J Hepatol
, vol.13
, pp. 372-374
-
-
Scheuer, P.J.1
-
147
-
-
50649112802
-
Treatment predictors of a sustained virologic response in hepatitis B and C
-
Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-51.
-
(2008)
J Hepatol
, vol.49
, pp. 634-651
-
-
Kau, A.1
Vermehren, J.2
Sarrazin, C.3
-
148
-
-
77949831342
-
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study
-
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 2010;138:1338-45.
-
(2010)
Gastroenterology
, vol.138
, pp. 1338-1345
-
-
Rauch, A.1
Kutalik, Z.2
Descombes, P.3
Cai, T.4
Di Iulio, J.5
Mueller, T.6
-
149
-
-
33645965496
-
Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C
-
Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8.
-
(2006)
Gut
, vol.55
, pp. 1332-1338
-
-
Grieve, R.1
Roberts, J.2
Wright, M.3
Sweeting, M.4
Deangelis, D.5
Rosenberg, W.6
-
150
-
-
72949098676
-
Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C
-
Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 2010;17:34-50.
-
(2010)
J Viral Hepat
, vol.17
, pp. 34-50
-
-
Sroczynski, G.1
Esteban, E.2
Conrads-Frank, A.3
Schwarzer, R.4
Muhlberger, N.5
Wright, D.6
-
152
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
Muir, A.J.4
Galler, G.W.5
McCone, J.6
-
153
-
-
34547395999
-
Overestimation and under-estimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method
-
Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and under-estimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007;46:22-31.
-
(2007)
Hepatology
, vol.46
, pp. 22-31
-
-
Chevaliez, S.1
Bouvier-Alias, M.2
Brillet, R.3
Pawlotsky, J.M.4
-
154
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
-
155
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales Jr., F.L.6
-
156
-
-
77957953601
-
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
-
Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010;52:1225-31.
-
(2010)
Hepatology
, vol.52
, pp. 1225-1231
-
-
Roomer, R.1
Hansen, B.E.2
Janssen, H.L.3
De Knegt, R.J.4
-
157
-
-
0036830507
-
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
-
Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
-
(2002)
Hepatology
, vol.36
, pp. 1273-1279
-
-
Soza, A.1
Everhart, J.E.2
Ghany, M.G.3
Doo, E.4
Heller, T.5
Promrat, K.6
-
158
-
-
0030927636
-
Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy
-
Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10.
-
(1997)
Hepatology
, vol.26
, pp. 206-210
-
-
Deutsch, M.1
Dourakis, S.2
Manesis, E.K.3
Gioustozi, A.4
Hess, G.5
Horsch, A.6
-
159
-
-
36549047972
-
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
-
McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36.
-
(2007)
N Engl J Med
, vol.357
, pp. 2227-2236
-
-
McHutchison, J.G.1
Dusheiko, G.2
Shiffman, M.L.3
Rodriguez-Torres, M.4
Sigal, S.5
Bourliere, M.6
-
160
-
-
78049460599
-
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
-
Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602-11.
-
(2010)
Gastroenterology
, vol.139
, pp. 1602-1611
-
-
Sulkowski, M.S.1
Shiffman, M.L.2
Afdhal, N.H.3
Reddy, K.R.4
McCone, J.5
Lee, W.M.6
-
161
-
-
10644237092
-
Epoetin alfa improves quality of life in anemic HCV infected patients receiving combination therapy
-
Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
-
(2004)
Hepatology
, vol.40
, pp. 1450-1458
-
-
Pockros, P.J.1
Shiffman, M.L.2
Schiff, E.R.3
Sulkowski, M.S.4
Younossi, Z.5
Dieterich, D.T.6
-
162
-
-
34548319085
-
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
-
Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9.
-
(2007)
Hepatology
, vol.46
, pp. 371-379
-
-
Shiffman, M.L.1
Salvatore, J.2
Hubbard, S.3
Price, A.4
Sterling, R.K.5
Stravitz, R.T.6
-
163
-
-
33845641280
-
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy
-
Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44:1598-606.
-
(2006)
Hepatology
, vol.44
, pp. 1598-1606
-
-
Del Rio, R.A.1
Post, A.B.2
Singer, M.E.3
-
164
-
-
40349103260
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
-
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
-
(2008)
JAMA
, vol.299
, pp. 914-924
-
-
Bennett, C.L.1
Silver, S.M.2
Djulbegovic, B.3
Samaras, A.T.4
Blau, C.A.5
Gleason, K.J.6
-
165
-
-
84863896049
-
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: A randomized trial
-
Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, et al. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: A randomized trial. Ann Intern Med. 2012;157: 94-103.
-
(2012)
Ann Intern Med.
, vol.157
, pp. 94-103
-
-
Schaefer, M.1
Sarkar, R.2
Knop, V.3
Effenberger, S.4
Friebe, A.5
Heinze, L.6
-
166
-
-
69249227492
-
Hepatitis C treatment in patients with drug addiction: Clinical management of interferon-alpha-associated psychiatric side effects
-
Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: Clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev 2008;1:177-87.
-
(2008)
Curr Drug Abuse Rev
, vol.1
, pp. 177-187
-
-
Schaefer, M.1
Mauss, S.2
-
167
-
-
0036788338
-
Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C
-
McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
-
(2002)
Gastroenterology
, vol.123
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
Poynard, T.4
Lindsay, K.L.5
Trepo, C.6
-
168
-
-
0043037223
-
High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C
-
Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
-
(2003)
Hepatology
, vol.38
, pp. 639-644
-
-
Bressler, B.L.1
Guindi, M.2
Tomlinson, G.3
Heathcote, J.4
-
169
-
-
72549099803
-
Insulin resistance and geographical origin: Major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4
-
Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, et al. Insulin resistance and geographical origin: Major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009;58:1662-9.
-
(2009)
Gut
, vol.58
, pp. 1662-1669
-
-
Moucari, R.1
Ripault, M.P.2
Martinot-Peignoux, M.3
Voitot, H.4
Cardoso, A.C.5
Stern, C.6
-
170
-
-
77956343048
-
Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients
-
Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1970-1977
-
-
Khattab, M.1
Eslam, M.2
Sharwae, M.A.3
Shatat, M.4
Ali, A.5
Hamdy, L.6
-
171
-
-
64549090121
-
Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: Ribavirin therapy
-
Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: Ribavirin therapy. J Viral Hepat 2008;15:591-9.
-
(2008)
J Viral Hepat
, vol.15
, pp. 591-599
-
-
Derbala, M.F.1
El Dweik, N.Z.2
Al Kaabi, S.R.3
Al-Marri, A.D.4
Pasic, F.5
Bener, A.B.6
-
172
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
SPRINT-2 Investigators
-
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone Jr., J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
-
173
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
-
174
-
-
47749115740
-
Meta-analysis: The outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
-
Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: The outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008;28:397-404.
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 397-404
-
-
Andriulli, A.1
Mangia, A.2
Iacobellis, A.3
Ippolito, A.4
Leandro, G.5
Zeuzem, S.6
-
175
-
-
79960453276
-
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
-
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
-
(2011)
J Hepatol
, vol.55
, pp. 245-264
-
-
-
176
-
-
79952726508
-
Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials
-
D'Heygere F, George C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol. 2011;83(5):815-9.
-
(2011)
J Med Virol.
, vol.83
, Issue.5
, pp. 815-819
-
-
D'Heygere, F.1
George, C.2
Van Vlierberghe, H.3
Decaestecker, J.4
Nakad, A.5
Adler, M.6
-
177
-
-
41549169618
-
Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5
-
Antaki N, Hermes A, Hadad M, Ftayeh M, Antaki F, Abdo N, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008;15:383-6.
-
(2008)
J Viral Hepat
, vol.15
, pp. 383-386
-
-
Antaki, N.1
Hermes, A.2
Hadad, M.3
Ftayeh, M.4
Antaki, F.5
Abdo, N.6
-
178
-
-
33746464994
-
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
-
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006;24:593-600.
-
(2006)
Aliment Pharmacol Ther
, vol.24
, pp. 593-600
-
-
Bonny, C.1
Fontaine, H.2
Poynard, T.3
Hézode, C.4
Larrey, D.5
Marcellin, P.6
-
179
-
-
43549108337
-
Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin
-
Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008;103:1131-5.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1131-1135
-
-
Nguyen, M.H.1
Trinh, H.N.2
Garcia, R.3
Nguyen, G.4
Lam, K.D.5
Keeffe, E.B.6
-
180
-
-
77950607734
-
High response rate of combination therapy of pegylated interferon and ribavirin in treating chronic hepatitis C with genotype 6A in Hong Kong Chinese
-
Li F, Ng TL, Tai LF, et al. High response rate of combination therapy of pegylated interferon and ribavirin in treating chronic hepatitis C with genotype 6A in Hong Kong Chinese. Hepatol Int 2009;3:164.
-
(2009)
Hepatol Int
, vol.3
, pp. 164
-
-
Li, F.1
Ng, T.L.2
Tai, L.F.3
-
181
-
-
59949093095
-
What is the safe duration of therapy for patients infected with HCV genotype 6
-
Antaki N, Marcellin P. What is the safe duration of therapy for patients infected with HCV genotype 6? Nat Clin Pract Gastroenterol Hepatol 2009;6:78-9.
-
(2009)
Nat Clin Pract Gastroenterol Hepatol
, vol.6
, pp. 78-79
-
-
Antaki, N.1
Marcellin, P.2
-
182
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
-
(2011)
N Engl J Med
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
Nelson, D.R.4
Sulkowski, M.S.5
Everson, G.T.6
-
183
-
-
79956074037
-
Management of hepatitis C virus genotype 4: Recommendations of an international expert panel
-
Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: Recommendations of an international expert panel. J Hepatol 2011;54:1250-62.
-
(2011)
J Hepatol
, vol.54
, pp. 1250-1262
-
-
Khattab, M.A.1
Ferenci, P.2
Hadziyannis, S.J.3
Colombo, M.4
Manns, M.P.5
Almasio, P.L.6
-
184
-
-
4344635133
-
Combination therapy of peginterferon alfa-2a (40KD) (PEGASYS(r)) and ribavirin (COPEGUS(r)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia
-
Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M. Combination therapy of peginterferon alfa-2a (40KD) (PEGASYS(r)) and ribavirin (COPEGUS(r)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003;38(4 Suppl. 1):636A.
-
(2003)
Hepatology
, vol.38
, Issue.4 SUPPL. 1
-
-
Shobokshi, O.A.1
Serebour, F.E.2
Skakni, L.3
Al Khalifa, M.4
-
185
-
-
19944409281
-
Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4
-
Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568-74.
-
(2004)
Liver Int
, vol.24
, pp. 568-574
-
-
Alfaleh, F.Z.1
Hadad, Q.2
Khuroo, M.S.3
Aljumah, A.4
Algamedi, A.5
Alashgar, H.6
-
186
-
-
42149150453
-
Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: A tertiary care center experience
-
Al Ashgar H, Khan MQ, Helmy A, Al Swat K, Al Shehri A, Al Kalbani A, et al. Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: A tertiary care center experience. Saudi J Gastroenterol 2008;14:58-65.
-
(2008)
Saudi J Gastroenterol
, vol.14
, pp. 58-65
-
-
Al Ashgar, H.1
Khan, M.Q.2
Helmy, A.3
Al Swat, K.4
Al Shehri, A.5
Al Kalbani, A.6
-
187
-
-
72049099330
-
Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population
-
Dahlan Y, Ather HM, Al-ahmadi M, Batwa F, Al-hamoudi W. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. World J Gastroenterol 2009;15:4429-33.
-
(2009)
World J Gastroenterol
, vol.15
, pp. 4429-4433
-
-
Dahlan, Y.1
Ather, H.M.2
Al-Ahmadi, M.3
Batwa, F.4
Al-Hamoudi, W.5
-
188
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
-
(2005)
J Hepatol
, vol.43
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
Smith, C.I.4
Marinos, G.5
Goncales Jr., F.L.6
-
189
-
-
48749099989
-
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
-
Austrian Hepatitis Study Group
-
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al.; Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
-
(2008)
Gastroenterology
, vol.135
, pp. 451-458
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
Gschwantler, M.4
Maieron, A.5
Brunner, H.6
-
190
-
-
38649090068
-
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
-
Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42.
-
(2008)
Hepatology
, vol.47
, pp. 35-42
-
-
Dalgard, O.1
Bjoro, K.2
Ring-Larsen, H.3
Bjornsson, E.4
Holberg-Petersen, M.5
Skovlund, E.6
-
191
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
-
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60.
-
(2006)
Hepatology
, vol.43
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
Pockros, P.J.4
Reddy, K.R.5
Hadziyannis, S.J.6
-
192
-
-
0037371144
-
Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy
-
Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-9.
-
(2003)
Hepatology
, vol.37
, pp. 600-609
-
-
Berg, T.1
Sarrazin, C.2
Herrmann, E.3
Hinrichsen, H.4
Gerlach, T.5
Zachoval, R.6
-
193
-
-
0041822106
-
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
-
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
-
(2003)
Hepatology
, vol.38
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.G.3
Manns, M.P.4
Harvey, J.5
Albrecht, J.6
-
194
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
-
(2006)
J Hepatol
, vol.44
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
Sperl, J.4
Horsmans, Y.5
Cianciara, J.6
-
195
-
-
37749046123
-
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
-
Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007;46:1732-40.
-
(2007)
Hepatology
, vol.46
, pp. 1732-1740
-
-
Kamal, S.M.1
El Kamary, S.S.2
Shardell, M.D.3
Hashem, M.4
Ahmed, I.N.5
Muhammadi, M.6
-
196
-
-
20544443172
-
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
-
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
-
(2005)
N Engl J Med
, vol.352
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
Ricci, G.L.4
Carretta, V.5
Persico, M.6
-
197
-
-
23244457832
-
Peginterferon-alpha-2a (40 kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
-
von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40 kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
-
(2005)
Gastroenterology
, vol.129
, pp. 522-527
-
-
Von Wagner, M.1
Huber, M.2
Berg, T.3
Hinrichsen, H.4
Rasenack, J.5
Heintges, T.6
-
198
-
-
34147207791
-
A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
-
Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.
-
(2007)
Gut
, vol.56
, pp. 553-559
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
Hou, N.J.4
Lee, L.P.5
Hsieh, M.Y.6
-
199
-
-
34447318385
-
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
-
Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
-
(2007)
N Engl J Med
, vol.357
, pp. 124-134
-
-
Shiffman, M.L.1
Suter, F.2
Bacon, B.R.3
Nelson, D.4
Harley, H.5
Sola, R.6
-
200
-
-
33645992473
-
Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
-
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
-
(2006)
Gastroenterology
, vol.130
, pp. 1086-1097
-
-
Berg, T.1
Von Wagner, M.2
Nasser, S.3
Sarrazin, C.4
Heintges, T.5
Gerlach, T.6
-
201
-
-
37749051824
-
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders
-
Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94.
-
(2007)
Hepatology
, vol.46
, pp. 1688-1694
-
-
Pearlman, B.L.1
Ehleben, C.2
Saifee, S.3
-
202
-
-
77957128536
-
Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection
-
Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2010;8:884-90.
-
(2010)
Clin Gastroenterol Hepatol
, vol.8
, pp. 884-890
-
-
Farnik, H.1
Lange, C.M.2
Sarrazin, C.3
Kronenberger, B.4
Zeuzem, S.5
Herrmann, E.6
-
203
-
-
75449111848
-
Peginterferon a-2a/ribavirin for 72 weeks reduces relapse among Hepatitis C type 1 and 4 patients with early virologic responses
-
Ferenci P, Laferl H, Scherzer TM, Andreas Maieron A, Hofer H, Stauber R, et al. Peginterferon a-2a/ribavirin for 72 weeks reduces relapse among Hepatitis C type 1 and 4 patients with early virologic responses. Gastroenterology 2010;138:503-12.
-
(2010)
Gastroenterology
, vol.138
, pp. 503-512
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
Andreas Maieron, A.4
Hofer, H.5
Stauber, R.6
-
204
-
-
33746564989
-
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
-
Sanchez-Tapias JM, Diago M, Escartin P, Enríquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
-
(2006)
Gastroenterology
, vol.131
, pp. 451-460
-
-
Sanchez-Tapias, J.M.1
Diago, M.2
Escartin, P.3
Enríquez, J.4
Romero-Gómez, M.5
Bárcena, R.6
-
205
-
-
33646001297
-
Pegylated interferon alfa-2b plus ribavirin in the re-treatment of interferon- ribavirin non-responder patients
-
Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the re-treatment of interferon- ribavirin non-responder patients. Gastroenterology 2006;130:1098-106.
-
(2006)
Gastroenterology
, vol.130
, pp. 1098-1106
-
-
Taliani, G.1
Gemignani, G.2
Ferrari, C.3
Aceti, A.4
Bartolozzi, D.5
Blanc, P.L.6
-
206
-
-
11144358311
-
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
-
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23;
-
(2004)
Gastroenterology
, vol.126
, pp. 1015-1023
-
-
Shiffman, M.L.1
Di Bisceglie, A.M.2
Lindsay, K.L.3
Morishima, C.4
Wright, E.C.5
Everson, G.T.6
-
207
-
-
33644646748
-
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the re-treatment of chronic hepatitis C
-
Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the re-treatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 2453-2462
-
-
Jacobson, I.M.1
Gonzalez, S.A.2
Ahmed, F.3
Lebovics, E.4
Min, A.D.5
Bodenheimer Jr., H.C.6
-
208
-
-
33847198680
-
Pegylated interferon and ribavirin failures: Is re-treatment an option
-
Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: Is re-treatment an option? Dig Dis Sci 2007;52:732-6.
-
(2007)
Dig Dis Sci
, vol.52
, pp. 732-736
-
-
Cheruvattath, R.1
Rosati, M.J.2
Gautam, M.3
Vargas, H.E.4
Rakela, J.5
Balan, V.6
-
209
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
-
210
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
Terrault, N.A.4
Jacobson, I.M.5
Afdhal, N.H.6
-
211
-
-
65549091525
-
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy
-
Pegasys Study Group
-
Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschênes M, Marotta PJ, et al.;Pegasys Study Group. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009;23:180-4.
-
(2009)
Can J Gastroenterol
, vol.23
, pp. 180-184
-
-
Yoshida, E.M.1
Sherman, M.2
Bain, V.G.3
Cooper, C.L.4
Deschênes, M.5
Marotta, P.J.6
-
212
-
-
57349116772
-
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
-
DiBisceglie A, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41.
-
(2008)
N Engl J Med
, vol.359
, pp. 2429-2441
-
-
Dibisceglie, A.1
Shiffman, M.L.2
Everson, G.T.3
Lindsay, K.L.4
Everhart, J.E.5
Wright, E.C.6
-
213
-
-
79958177731
-
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
-
EPIC3 Study Group
-
Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al.; EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990-9.
-
(2011)
Gastroenterology
, vol.140
, pp. 1990-1999
-
-
Bruix, J.1
Poynard, T.2
Colombo, M.3
Schiff, E.4
Burak, K.5
Heathcote, E.J.6
-
214
-
-
84857395452
-
Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders
-
Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2012;55:742-8.
-
(2012)
Hepatology
, vol.55
, pp. 742-748
-
-
Chayama, K.1
Takahashi, S.2
Toyota, J.3
Karino, Y.4
Ikeda, K.5
Ishikawa, H.6
-
215
-
-
78751634051
-
High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study
-
Jensen DM, Wedemeyer H, Herring RW, Ferenci P, Ma MM, Zeuzem S, et al. High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study. Hepatology 2010;52:360A.
-
(2010)
Hepatology
, vol.52
-
-
Jensen, D.M.1
Wedemeyer, H.2
Herring, R.W.3
Ferenci, P.4
Ma, M.M.5
Zeuzem, S.6
-
216
-
-
0038575483
-
Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance
-
Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8.
-
(2003)
Gastroenterology
, vol.125
, pp. 80-88
-
-
Gerlach, J.T.1
Diepolder, H.M.2
Zachoval, R.3
Gruener, N.H.4
Jung, M.C.5
Ulsenheimer, A.6
-
217
-
-
0041766186
-
Natural course of acute hepatitis C: A long-term prospective study
-
Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, et al. Natural course of acute hepatitis C: A long-term prospective study. Dig Liver Dis 2003;35:104-13.
-
(2003)
Dig Liver Dis
, vol.35
, pp. 104-113
-
-
Santantonio, T.1
Sinisi, E.2
Guastadisegni, A.3
Casalino, C.4
Mazzola, M.5
Gentile, A.6
-
218
-
-
33644857481
-
Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response
-
Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-8.
-
(2006)
Gastroenterology
, vol.130
, pp. 632-638
-
-
Kamal, S.M.1
Fouly, A.E.2
Kamel, R.R.3
Hockenjos, B.4
Al Tawil, A.5
Khalifa, K.E.6
-
219
-
-
0036369286
-
Interferon for acute hepatitis C
-
Poynard T, Regimbeau C, Myers RP, Thevenot T, Leroy V, Mathurin P, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002;CD000369.
-
(2002)
Cochrane Database Syst Rev
-
-
Poynard, T.1
Regimbeau, C.2
Myers, R.P.3
Thevenot, T.4
Leroy, V.5
Mathurin, P.6
-
220
-
-
43549109840
-
Acute hepatitis C. A systematic review
-
Kamal SM. Acute hepatitis C: A systematic review. Am J Gastroenterol 2008;103:1283-97.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1283-1297
-
-
Kamal, S.M.1
-
221
-
-
0346243740
-
When and how to treat acute hepatitis C
-
Licata A, Di Bona D, Schepis F, Shahied L, Craxí A, Cammà C. When and how to treat acute hepatitis C? J Hepatol 2003;39:1056-62.
-
(2003)
J Hepatol
, vol.39
, pp. 1056-1062
-
-
Licata, A.1
Di Bona, D.2
Schepis, F.3
Shahied, L.4
Craxí, A.5
Cammà, C.6
-
222
-
-
74549138969
-
Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV III study-A randomized controlled study
-
The Hep-Net Acute-HCV Study group
-
Deterding K, Gruner NH, Wiegand J, Galle P, Spengler U, Hinrichsen H, et al.; The Hep-Net Acute-HCV Study group. Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV III study-a randomized controlled study. J Hepatol 2009;50(Suppl 1):S380.
-
(2009)
J Hepatol
, vol.50
, Issue.SUPPL. 1
-
-
Deterding, K.1
Gruner, N.H.2
Wiegand, J.3
Galle, P.4
Spengler, U.5
Hinrichsen, H.6
-
223
-
-
50549094817
-
Acute hepatitis C: Current status and remaining challenges
-
Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: Current status and remaining challenges. J Hepatol 2008;49:625-33.
-
(2008)
J Hepatol
, vol.49
, pp. 625-633
-
-
Santantonio, T.1
Wiegand, J.2
Gerlach, J.T.3
-
224
-
-
33646562220
-
Duration of peginterferon therapy in acute hepatitis C: A randomized trial
-
Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology 2006;43:923-31.
-
(2006)
Hepatology
, vol.43
, pp. 923-931
-
-
Kamal, S.M.1
Moustafa, K.N.2
Chen, J.3
Fehr, J.4
Abdel Moneim, A.5
Khalifa, K.E.6
-
225
-
-
1542378867
-
Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C-A randomized study of treatment duration and ribavirin dose
-
PEGASYS international study group
-
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS international study group. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C-A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr., H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
-
226
-
-
0034619980
-
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
-
Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
-
(2000)
N Engl J Med
, vol.343
, pp. 1673-1680
-
-
Heathcote, E.J.1
Shiffman, M.L.2
Cooksley, W.G.3
Dusheiko, G.M.4
Lee, S.S.5
Balart, L.6
-
227
-
-
33750078958
-
HCV-related advanced fibrosis/cirrhosis: Randomized controlled trial of pegylated interferon alpha-2a and ribavirin
-
Helbling B, Jochum W, Stamenic I, Knopfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: Randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006;13:762-9.
-
(2006)
J Viral Hepat
, vol.13
, pp. 762-769
-
-
Helbling, B.1
Jochum, W.2
Stamenic, I.3
Knopfli, M.4
Cerny, A.5
Borovicka, J.6
-
228
-
-
21044459011
-
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens
-
Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20.
-
(2005)
Gut
, vol.54
, pp. 1014-1020
-
-
Schmid, M.1
Kreil, A.2
Jessner, W.3
Homoncik, M.4
Datz, C.5
Gangl, A.6
-
229
-
-
0036189531
-
Hepatitis C virus kinetics during and immediately after liver transplantation
-
Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7.
-
(2002)
Hepatology
, vol.35
, pp. 680-687
-
-
Garcia-Retortillo, M.1
Forns, X.2
Feliu, A.3
Moitinho, E.4
Costa, J.5
Navasa, M.6
-
230
-
-
17944382023
-
A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients
-
discussion 393-394
-
Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384- 93;discussion 393-394.
-
(2001)
Ann Surg
, vol.234
, pp. 384-393
-
-
Ghobrial, R.M.1
Steadman, R.2
Gornbein, J.3
Lassman, C.4
Holt, C.D.5
Chen, P.6
-
231
-
-
0742321955
-
Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up
-
Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004;77:226-31.
-
(2004)
Transplantation
, vol.77
, pp. 226-231
-
-
Neumann, U.P.1
Berg, T.2
Bahra, M.3
Puhl, G.4
Guckelberger, O.5
Langrehr, J.M.6
-
232
-
-
0036245493
-
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation
-
Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-5.
-
(2002)
Liver Transpl
, vol.8
, pp. 350-355
-
-
Crippin, J.S.1
McCashland, T.2
Terrault, N.3
Sheiner, P.4
Charlton, M.R.5
-
233
-
-
33845647232
-
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study
-
Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. J Hepatol 2007;46:206-12.
-
(2007)
J Hepatol
, vol.46
, pp. 206-212
-
-
Iacobellis, A.1
Siciliano, M.2
Perri, F.3
Annicchiarico, B.E.4
Leandro, G.5
Caruso, N.6
-
234
-
-
10744234013
-
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation
-
Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-96.
-
(2003)
J Hepatol
, vol.39
, pp. 389-396
-
-
Forns, X.1
Garcia-Retortillo, M.2
Serrano, T.3
Feliu, A.4
Suarez, F.5
De La Mata, M.6
-
235
-
-
61749085030
-
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study
-
Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009;50:719-28.
-
(2009)
J Hepatol
, vol.50
, pp. 719-728
-
-
Carrion, J.A.1
Martinez-Bauer, E.2
Crespo, G.3
Ramirez, S.4
Perez-Del-Pulgar, S.5
Garcia-Valdecasas, J.C.6
-
236
-
-
84855231089
-
Hepatitis C virus treatment pre- and post-liver transplantation
-
Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012;32 Suppl 1:120-8.
-
(2012)
Liver Int
, vol.32
, Issue.SUPPL. 1
, pp. 120-128
-
-
Roche, B.1
Samuel, D.2
-
237
-
-
34247266730
-
Management of hepatitis C infection after liver transplantation
-
Alsatie M, Chalasani N, Kwo PY. Management of hepatitis C infection after liver transplantation. Drugs 2007;67:871-85.
-
(2007)
Drugs
, vol.67
, pp. 871-885
-
-
Alsatie, M.1
Chalasani, N.2
Kwo, P.Y.3
-
238
-
-
37149032102
-
Experience with 122 consecutive liver transplant procedures at king faisal specialist hospital and research center
-
Al-Sebayel M, Khalaf H, Al-Sofayan M, Al-Saghier M, Abdo A, Al-Bahili H, et al. Experience with 122 consecutive liver transplant procedures at king faisal specialist hospital and research center. Ann Saudi Med 2007;27:333-8.
-
(2007)
Ann Saudi Med
, vol.27
, pp. 333-338
-
-
Al-Sebayel, M.1
Khalaf, H.2
Al-Sofayan, M.3
Al-Saghier, M.4
Abdo, A.5
Al-Bahili, H.6
-
239
-
-
0034070192
-
HCVrelated fibrosis progression following liver transplantation: Increase in recent years
-
Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCVrelated fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-84.
-
(2000)
J Hepatol
, vol.32
, pp. 673-684
-
-
Berenguer, M.1
Ferrell, L.2
Watson, J.3
Prieto, M.4
Kim, M.5
Rayon, M.6
-
240
-
-
7244247475
-
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
-
Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-6.
-
(2004)
J Hepatol
, vol.41
, pp. 830-836
-
-
Neumann, U.P.1
Berg, T.2
Bahra, M.3
Seehofer, D.4
Langrehr, J.M.5
Neuhaus, R.6
-
241
-
-
34547455714
-
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
-
Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13:975-83.
-
(2007)
Liver Transpl
, vol.13
, pp. 975-983
-
-
Yilmaz, N.1
Shiffman, M.L.2
Stravitz, R.T.3
Sterling, R.K.4
Luketic, V.A.5
Sanyal, A.J.6
-
242
-
-
39649100163
-
Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation
-
Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-87.
-
(2008)
Am J Transplant
, vol.8
, pp. 679-687
-
-
Berenguer, M.1
Palau, A.2
Aguilera, V.3
Rayon, J.M.4
Juan, F.S.5
Prieto, M.6
-
243
-
-
19944430229
-
Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials
-
Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;41:289-98.
-
(2005)
Hepatology
, vol.41
, pp. 289-298
-
-
Chalasani, N.1
Manzarbeitia, C.2
Ferenci, P.3
Vogel, W.4
Fontana, R.J.5
Voigt, M.6
-
244
-
-
11844249361
-
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation
-
Shergill A, Khalili M, Bollinger K, Roberts J, Ascher N, Terrault N. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J Transplant 2005;5:118-24.
-
(2005)
Am J Transplant
, vol.5
, pp. 118-124
-
-
Shergill, A.1
Khalili, M.2
Bollinger, K.3
Roberts, J.4
Ascher, N.5
Terrault, N.6
-
245
-
-
0034324083
-
Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group
-
Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-67.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 556-567
-
-
Glue, P.1
Fang, J.W.2
Rouzier-Panis, R.3
Raffanel, C.4
Sabo, R.5
Gupta, S.K.6
-
246
-
-
17344367725
-
The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
-
Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.Hepatology 1998;28:831-8.
-
(1998)
Hepatology
, vol.28
, pp. 831-838
-
-
Sheiner, P.A.1
Boros, P.2
Klion, F.M.3
Thung, S.N.4
Schluger, L.K.5
Lau, J.Y.6
-
247
-
-
0031887327
-
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial
-
Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation 1998;65:82-6.
-
(1998)
Transplantation
, vol.65
, pp. 82-86
-
-
Singh, N.1
Gayowski, T.2
Wannstedt, C.F.3
Shakil, A.O.4
Wagener, M.M.5
Fung, J.J.6
-
248
-
-
0031971088
-
A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation
-
Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-7.
-
(1998)
Hepatology
, vol.27
, pp. 1403-1407
-
-
Gane, E.J.1
Lo, S.K.2
Riordan, S.M.3
Portmann, B.C.4
Lau, J.Y.5
Naoumov, N.V.6
-
249
-
-
79959750829
-
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin
-
Al-Hamoudi W, Mohamed H, Abaalkhail F, Kamel Y, Al-Masri N, Allam N, et al. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci 2011;56:1848-52.
-
(2011)
Dig Dis Sci
, vol.56
, pp. 1848-1852
-
-
Al-Hamoudi, W.1
Mohamed, H.2
Abaalkhail, F.3
Kamel, Y.4
Al-Masri, N.5
Allam, N.6
-
250
-
-
79959561437
-
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus
-
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7.
-
(2011)
Hepatology
, vol.54
, pp. 20-27
-
-
Garg, V.1
Van Heeswijk, R.2
Lee, J.E.3
Alves, K.4
Nadkarni, P.5
Luo, X.6
-
251
-
-
0344120830
-
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection
-
Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13.
-
(2003)
Lancet
, vol.362
, pp. 1708-1713
-
-
Qurishi, N.1
Kreuzberg, C.2
Luchters, G.3
Effenberger, W.4
Kupfer, B.5
Sauerbruch, T.6
-
252
-
-
1842532135
-
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon a-2b+ full-course vs. 16-week delayed ribavirin
-
Bräu N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon a-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004;39:989-98.
-
(2004)
Hepatology
, vol.39
, pp. 989-998
-
-
Bräu, N.1
Rodriguez-Torres, M.2
Prokupek, D.3
Bonacini, M.4
Giffen, C.A.5
Smith, J.J.6
-
253
-
-
0344200080
-
Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users
-
Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 1999;15:699-704.
-
(1999)
Eur J Epidemiol
, vol.15
, pp. 699-704
-
-
Pallas, J.R.1
Farinas-Alvarez, C.2
Prieto, D.3
Delgado-Rodriguez, M.4
-
254
-
-
14844333245
-
Prevalence of HBV and HCV dual infection in patients on hemodialysis
-
Reddy GA, Dakshinamurthy KV, Neelaprasad P, Gangadhar T, Lakshmi V. Prevalence of HBV and HCV dual infection in patients on hemodialysis. Indian J Med Microbiol 2005;23:41-3.
-
(2005)
Indian J Med Microbiol
, vol.23
, pp. 41-43
-
-
Reddy, G.A.1
Dakshinamurthy, K.V.2
Neelaprasad, P.3
Gangadhar, T.4
Lakshmi, V.5
-
255
-
-
20844435963
-
Natural history of hepatitis B and C in renal allograft recipients
-
Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005;79:1132-6.
-
(2005)
Transplantation
, vol.79
, pp. 1132-1136
-
-
Aroldi, A.1
Lampertico, P.2
Montagnino, G.3
Passerini, P.4
Villa, M.5
Campise, M.R.6
-
256
-
-
34547983689
-
Hepatitis B and C virus coinfection in the TREAT Asia HIV Observational Database
-
TREAT Asia HIV Observational Database
-
Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM; TREAT Asia HIV Observational Database. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510-8.
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 1510-1518
-
-
Zhou, J.1
Dore, G.J.2
Zhang, F.3
Lim, P.L.4
Chen, Y.M.5
-
258
-
-
53349148149
-
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha 2b and ribavirin in patients with HBV/HCV co-infection
-
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha 2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008;49:688-94.
-
(2008)
J Hepatol
, vol.49
, pp. 688-694
-
-
Potthoff, A.1
Wedemeyer, H.2
Boecher, W.O.3
Berg, T.4
Zeuzem, S.5
Arnold, J.6
-
259
-
-
72449191348
-
Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin
-
HEP-NET B/C Coinfection Study Group
-
Potthoff A, Berg T, Wedemeyer H; HEP-NET B/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009;44:1487-90.
-
(2009)
Scand J Gastroenterol
, vol.44
, pp. 1487-1490
-
-
Potthoff, A.1
Berg, T.2
Wedemeyer, H.3
-
260
-
-
34547839646
-
Diabetes mellitus after kidney transplantation: A French multicentre observational study
-
Kamar N, Mariat C, Delahousse M, Dantal J, Najjar AA, Cassuto E, et al. Diabetes mellitus after kidney transplantation: A French multicentre observational study. Nephrol Dial Transplant 2007;22:1986-93.
-
(2007)
Nephrol Dial Transplant
, vol.22
, pp. 1986-1993
-
-
Kamar, N.1
Mariat, C.2
Delahousse, M.3
Dantal, J.4
Najjar, A.A.5
Cassuto, E.6
-
261
-
-
33750005603
-
Recurrent glomerulonephritis after kidney transplantation
-
Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006;6:2535-42.
-
(2006)
Am J Transplant
, vol.6
, pp. 2535-2542
-
-
Choy, B.Y.1
Chan, T.M.2
Lai, K.N.3
-
262
-
-
1642502319
-
National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
-
National Kidney Foundation
-
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
-
(2003)
Ann Intern Med
, vol.139
, pp. 137-147
-
-
Levey, A.S.1
Coresh, J.2
Balk, E.3
Kausz, A.T.4
Levin, A.5
Steffes, M.W.6
-
263
-
-
33947159554
-
End-stage renal disease and hepatitis C infection: Comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage
-
Contreras AM, Ruiz I, Polanco-Cruz G, Monteon FJ, Celis A, Vazquez G, et al. End-stage renal disease and hepatitis C infection: Comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol 2007;6:48-54.
-
(2007)
Ann Hepatol
, vol.6
, pp. 48-54
-
-
Contreras, A.M.1
Ruiz, I.2
Polanco-Cruz, G.3
Monteon, F.J.4
Celis, A.5
Vazquez, G.6
-
264
-
-
79951699393
-
Low-dose peginterferon alfa-2a (40KD) is safe and produces a SVR in patients with chronic hepatitis C and end-stage renal disease
-
Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, et al. Low-dose peginterferon alfa-2a (40KD) is safe and produces a SVR in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011;9:242-8.
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 242-248
-
-
Peck-Radosavljevic, M.1
Boletis, J.2
Besisik, F.3
Ferraz, M.L.4
Alric, L.5
Samuel, D.6
-
265
-
-
0031593545
-
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications
-
Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998;9:2344-8.
-
(1998)
J Am Soc Nephrol
, vol.9
, pp. 2344-2348
-
-
Rostaing, L.1
Chatelut, E.2
Payen, J.L.3
Izopet, J.4
Thalamas, C.5
Ton-That, H.6
-
266
-
-
79958287999
-
Combined antiviral therapy of hepatitis C virus in dialysis patients: Meta-analysis of clinical trials
-
Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: Meta-analysis of clinical trials. J Viral Hepat 2011;18:e263-9.
-
(2011)
J Viral Hepat
, vol.18
-
-
Fabrizi, F.1
Dixit, V.2
Martin, P.3
Messa, P.4
-
267
-
-
79961174592
-
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: A single Saudi center experience
-
Alsaran K, Sabry A, Shaheen N. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: A single Saudi center experience. Int Urol Nephrol 2010;43:865-73.
-
(2010)
Int Urol Nephrol
, vol.43
, pp. 865-873
-
-
Alsaran, K.1
Sabry, A.2
Shaheen, N.3
-
268
-
-
0033060493
-
Interferon-alpha in chronic hepatitis C infection in dialysis patients
-
Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999;34:55-60.
-
(1999)
Am J Kidney Dis
, vol.34
, pp. 55-60
-
-
Huraib, S.1
Tanimu, D.2
Romeh, S.A.3
Quadri, K.4
Al Ghamdi, G.5
Iqbal, A.6
-
269
-
-
33645969906
-
Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients
-
Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-21.
-
(2006)
J Viral Hepat
, vol.13
, pp. 316-321
-
-
Bruchfeld, A.1
Lindahl, K.2
Reichard, O.3
Carlsson, T.4
Schvarcz, R.5
-
270
-
-
50549090087
-
Hepatitis C virus and kidney disease
-
Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol 2008;49:613-24.
-
(2008)
J Hepatol
, vol.49
, pp. 613-624
-
-
Martin, P.1
Fabrizi, F.2
-
271
-
-
0032533428
-
Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: Response to interferon-alpha therapy
-
Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998;66:1254-8.
-
(1998)
Transplantation
, vol.66
, pp. 1254-1258
-
-
Toth, C.M.1
Pascual, M.2
Chung, R.T.3
Graeme-Cook, F.4
Dienstag, J.L.5
Bhan, A.K.6
-
272
-
-
84855529607
-
Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients
-
Aljumah AA, Saeed MA, Al Flaiw AI, Al Traif IH, Al Alwan AM, Al Qurashi SH, et al. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J Gastroenterol 2012;18:55-63.
-
(2012)
World J Gastroenterol
, vol.18
, pp. 55-63
-
-
Aljumah, A.A.1
Saeed, M.A.2
Al Flaiw, A.I.3
Al Traif, I.H.4
Al Alwan, A.M.5
Al Qurashi, S.H.6
-
273
-
-
84874756823
-
Peginterferon alpha- 2a plus ribavirin combination treatment in chronic hepatitis C post-renal transplant patients: An interim analysis
-
Sanai F, Bzeizi KI, Almeshari KA, Mousa D, Ashgar H, ALshoail G, et al. Peginterferon alpha- 2a plus ribavirin combination treatment in chronic hepatitis C post-renal transplant patients: An interim analysis. Transplantation 2010;90(Suppl 2):222.
-
(2010)
Transplantation
, vol.90
, Issue.SUPPL. 2
, pp. 222
-
-
Sanai, F.1
Bzeizi, K.I.2
Almeshari, K.A.3
Mousa, D.4
Ashgar, H.5
Alshoail, G.6
-
274
-
-
0345517249
-
Interferon-alpha may exacerbate cryoblobulinemiarelated ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity
-
Cid MC, Hernandez-Rodriguez J, Robert J, del Rio A, Casademont J, Coll-Vinent B, et al. Interferon-alpha may exacerbate cryoblobulinemiarelated ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 1999;42:1051-5.
-
(1999)
Arthritis Rheum
, vol.42
, pp. 1051-1055
-
-
Cid, M.C.1
Hernandez-Rodriguez, J.2
Robert, J.3
Del Rio, A.4
Casademont, J.5
Coll-Vinent, B.6
-
276
-
-
0032855572
-
Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia
-
Calleja JL, Albillos A, Moreno-Otero R, Rossi I, Cacho G, Domper F, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999;13:1179-86.
-
(1999)
Aliment Pharmacol Ther
, vol.13
, pp. 1179-1186
-
-
Calleja, J.L.1
Albillos, A.2
Moreno-Otero, R.3
Rossi, I.4
Cacho, G.5
Domper, F.6
-
277
-
-
0033818316
-
Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinaemia with ribavirin and interferon-alpha
-
Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinaemia with ribavirin and interferon- alpha. J Rheumatol 2000;27:2172-8.
-
(2000)
J Rheumatol
, vol.27
, pp. 2172-2178
-
-
Zuckerman, E.1
Keren, D.2
Slobodin, G.3
Rosner, I.4
Rozenbaum, M.5
Toubi, E.6
-
278
-
-
31544469250
-
Treatment of hepatitis C-virus-related glomerulonephritis
-
Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436-9.
-
(2006)
Kidney Int
, vol.69
, pp. 436-439
-
-
Kamar, N.1
Rostaing, L.2
Alric, L.3
-
279
-
-
2442665224
-
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
-
Atlantic Coast Hepatitis Treatment Group
-
Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
-
(2004)
N Engl J Med
, vol.350
, pp. 2265-2271
-
-
Muir, A.J.1
Bornstein, J.D.2
Killenberg, P.G.3
-
280
-
-
0041663624
-
Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency
-
Bruchfeld A, Lindahl K, Stahle L, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80.
-
(2003)
Nephrol Dial Transplant
, vol.18
, pp. 1573-1580
-
-
Bruchfeld, A.1
Lindahl, K.2
Stahle, L.3
Schvarcz, R.4
-
281
-
-
33646357877
-
Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study
-
VAHCV-001 Study Group
-
Anand BS, Currie S, Dieperink E, Bin EJ, Shen H, Ho SB, et al.; VAHCV- 001 Study Group. Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study. Gastroenterology 2006;130:1607-16.
-
(2006)
Gastroenterology
, vol.130
, pp. 1607-1616
-
-
Anand, B.S.1
Currie, S.2
Dieperink, E.3
Bin, E.J.4
Shen, H.5
Ho, S.B.6
-
282
-
-
0036829486
-
Prevention and treatment of hepatitis C in injection drug users
-
Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36:S210-9.
-
(2002)
Hepatology
, vol.36
-
-
Edlin, B.R.1
-
283
-
-
0034118647
-
Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions
-
Trask PC, Esper P, Riba M,Redman B. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-26.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2316-2326
-
-
Trask, P.C.1
Esper, P.2
Riba, M.3
Redman, B.4
-
284
-
-
36348986800
-
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects
-
Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 2007;46:991-8.
-
(2007)
Hepatology
, vol.46
, pp. 991-998
-
-
Schaefer, M.1
Hinzpeter, A.2
Mohmand, A.3
Janssen, G.4
Pich, M.5
Schwaiger, M.6
-
285
-
-
48749083577
-
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia
-
Thalassemia Clinical Research Network
-
Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al.; Thalassemia Clinical Research Network. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Hematologica 2008;93:1247-51.
-
(2008)
Hematologica
, vol.93
, pp. 1247-1251
-
-
Harmatz, P.1
Jonas, M.M.2
Kwiatkowski, J.L.3
Wright, E.C.4
Fischer, R.5
Vichinsky, E.6
-
286
-
-
84867302369
-
Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia
-
Issa H. Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. World J Hepatol 2010;2:180-4.
-
(2010)
World J Hepatol
, vol.2
, pp. 180-184
-
-
Issa, H.1
-
287
-
-
67649342202
-
Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease
-
Ayyub MA, El-Moursy SA, Khazindar AM, Abbas FA. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease. Saudi Med J 2009;30:712-6.
-
(2009)
Saudi Med J
, vol.30
, pp. 712-716
-
-
Ayyub, M.A.1
El-Moursy, S.A.2
Khazindar, A.M.3
Abbas, F.A.4
|